Versican expression is associated with tumor-infiltrating CD8-positive T cells and infiltration depth in cervical cancer

Modern Pathology

Volumn 23, Issue 12, 2010, Pages 1605-1615

  Gorter, Arko ^a   Zijlmans, Henry J ^b   Van Gent, Hestia ^a   Trimbos, J Baptist ^a   Fleuren, Gert J ^a   Jordanova, Ekaterina S ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

cervical cancer; invasion; versican

Indexed keywords

MESSENGER RNA; VERSICAN;

ARTICLE; CD8+ T LYMPHOCYTE; CELL COUNT; CELL INFILTRATION; CELL POPULATION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MAJOR CLINICAL STUDY; MYOFIBROBLAST; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; STROMA; UTERINE CERVIX CANCER;

CD8-POSITIVE T-LYMPHOCYTES; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; LYMPHOCYTES, TUMOR-INFILTRATING; PROGNOSIS; PROTEIN ISOFORMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; STROMAL CELLS; TUMOR MARKERS, BIOLOGICAL; UTERINE CERVICAL NEOPLASMS; VERSICANS;

EID: 78649707805     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2010.154     Document Type: Article

References (48)

1. Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
2. Mbeunkui F, Johann Jr DJ. Cancer and the tumor microenvironment: a review of an essential relationship. Cancer Chemother Pharmacol 2009;63:571-582.
3. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002;420:860-867.
4. Jordanova ES, Gorter A, Ayachi O, et al. Human leukocyte antigen class I, MHC class I chain-related molecule A, and CD8+/regulatory T-cell ratio: which variable determines survival of cervical cancer patients- Clin Cancer Res 2008;14:2028-2035.
5. Ricciardelli C, Sakko AJ, Ween MP, et al. The biological role and regulation of versican levels in cancer. Cancer Metastasis Rev 2009;28:233-245.
6. Wight TN. Versican: a versatile extracellular matrix proteoglycan in cell biology. Curr Opin Cell Biol 2002;14:617-623.
7. Lemire JM, Braun KR, Maurel P, et al. Versican/PG-M isoforms in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 1999;19:1630-1639.
8. Kischel P, Waltregny D, Dumont B, et al. Versican overexpression in human breast cancer lesions: known and new isoforms for stromal tumor targeting. Int J Cancer 2010;126:640-650.
9. Perissinotto D, Iacopetti P, Bellina I, et al. Avian neural crest cell migration is diversely regulated by the two major hyaluronan-binding proteoglycans PG-M/versi-can and aggrecan. Development 2000;127:2823-2842.
10. Cattaruzza S, Schiappacassi M, Ljungberg-Rose A, et al. Distribution of PG-M/versican variants in human tissues and de novo expression of isoform V3 upon endothelial cell activation, migration, and neoangio-genesis in vitro. J Biol Chem 2002;277:47626-47635.
11. Sakko AJ, Ricciardelli C, Mayne K, et al. Versican accumulation in human prostatic fibroblast cultures is enhanced by prostate cancer cell-derived transforming growth factor beta1. Cancer Res 2001;61:926-930.
12. Ricciardelli C, Brooks JH, Suwiwat S, et al. Regulation of stromal versican expression by breast cancer cells and importance to relapse-free survival in patients with node-negative primary breast cancer. Clin Cancer Res 2002;8:1054-1060.
13. Nikitovic D, Zafiropoulos A, Katonis P, et al. Trans form-ing growth factor-beta as a key molecule triggering the expression of versican isoforms v0 and v1, hyaluronan synthase-2 and synthesis of hyaluronan in malignant osteosarcoma cells. IUBMB Life 2006;58:47-53.
14. Arslan F, Bosserhoff AK, Nickl-Jockschat T, et al. The role of versican isoforms V0/V1 in glioma migration mediated by transforming growth factor-beta2. Br J Cancer 2007;96:1560-1568.
15. Yang BL, Zhang Y, Cao L, et al. Cell adhesion and proliferation mediated through the G1 domain of versican. J Cell Biochem 1999;72:210-220. (Pubitemid 29021934)
16. Pirinen R, Leinonen T, Bohm J, et al. Versican in nonsmall cell lung cancer: relation to hyaluronan, clinicopathologic factors, and prognosis. Hum Pathol 2005;36:44-50.
17. Suwiwat S, Ricciardelli C, Tammi R, et al. Expression of extracellular matrix components versican, chondroitin sulfate, tenascin, and hyaluronan, and their association with disease outcome in node-negative breast cancer. Clin Cancer Res 2004;10: 2491-2498.
18. Voutilainen K, Anttila M, Sillanpaa S, et al. Versican in epithelial ovarian cancer: relation to hyaluronan, clinicopathologic factors and prognosis. Int J Cancer 2003;107:359-364.
19. Pukkila MJ, Kosunen AS, Virtaniemi JA, et al. Versican expression in pharyngeal squamous cell carcinoma: an immunohistochemical study. J Clin Pathol 2004;57: 735-739.
20. Kodama J, Hasengaowa, Kusumoto T, et al. Versican expression in human cervical cancer. Eur J Cancer 2007;43:1460-1466.
21. Isogai Z, Shinomura T, Yamakawa N, et al. 2B1 antigen characteristically expressed on extracellular matrices of human malignant tumors is a large chondroitin sulfate proteoglycan, PG-M/versican. Cancer Res 1996;56:3902-3908.
22. Gulyas M, Hjerpe A. Proteoglycans and WT1 as markers for distinguishing adenocarcinoma, epithe-lioid mesothelioma, and benign mesothelium. J Pathol 2003;199:479-487.
23. Touab M, Villena J, Barranco C, et al. Versican is differentially expressed in human melanoma and may play a role in tumor development. Am J Pathol 2002;160:549-557.
24. Skandalis SS, Theocharis AD, Theocharis DA, et al. Matrix proteoglycans are markedly affected in advanced laryngeal squamous cell carcinoma. Biochim Biophys Acta 2004;1689:152-161.
25. Theocharis AD. Human colon adenocarcinoma is associated with specific post-translational modifications of versican and decorin. Biochim Biophys Acta 2002;1588:165-172.
26. Theocharis AD, Tsara ME, Papageorgacopoulou N, et al. Pancreatic carcinoma is characterized by elevated content of hyaluronan and chondroitin sulfate with altered disaccharide composition. Biochim Biophys Acta 2000;1502:201-206.
27. Zijlmans HJ, Fleuren GJ, Baelde HJ, et al. Role of tumor-derived proinflammatory cytokines GM-CSF, TNF-alpha, and IL-12 in the migration and differentiation of antigen-presenting cells in cervical carcinoma. Cancer 2007;109:556-565.
28. Zijlmans HJ, Fleuren GJ, Baelde HJ, et al. The absence of CCL2 expression in cervical carcinoma is associated with increased survival and loss of heterozygosity at 17q11.2. J Pathol 2006;208:507-517.
29. Ruiter DJ, Ferrier CM, van Muijen GN, et al. Quality control of immunohistochemical evaluation of tumour-associated plasminogen activators and related components. European BIOMED-1 Concerted Action on Clinical Relevance of Proteases in Tumour Invasion and Metastasis. Eur J Cancer 1998;34:1334-1340.
30. Kloth JN, Fleuren GJ, Oosting J, et al. Substantial changes in gene expression of Wnt, MAPK and TNFalpha pathways induced by TGF-beta1 in cervical cancer cell lines. Carcinogenesis 2005;26:1493-1502.
31. Zhao X, Russell P. Versican splice variants in human trabecular meshwork and ciliary muscle. Mol Vis 2005;11:603-608.
32. Kloth JN, Gorter A, Fleuren GJ, et al. Elevated expression of SerpinA1 and SerpinA3 in HLA-positive cervical carcinoma. J Pathol 2008;215:222-230.
33. Sandel MH, Dadabayev AR, Menon AG, et al. Prognostic value of tumor-infiltrating dendritic cells in colorectal cancer: role of maturation status and intratumoral localization. Clin Cancer Res 2005;11:2576-2582.
34. Nara Y, Kato Y, Torii Y, et al. Immunohistochemical localization of extracellular matrix components in human breast tumours with special reference to PG-M/versican. Histochem J 1997;29:21-30.
35. Sheng W, Wang G, Wang Y, et al. The roles of versican V1 and V2 isoforms in cell proliferation and apoptosis. Mol Biol Cell 2005;16:1330-1340. (Pubitemid 40349568)
36. Ricciardelli C, Mayne K, Sykes PJ, et al. Elevated levels of versican but not decorin predict disease progression in early-stage prostate cancer. Clin Cancer Res 1998; 4:963-971.
37. Casey RC, Oegema Jr TR, Skubitz KM, et al. Cell membrane glycosylation mediates the adhesion, migration, and invasion of ovarian carcinoma cells. Clin Exp Metastasis 2003;20:143-152.
38. Mukaratirwa S, Koninkx JF, Gruys E, et al. Mutual paracrine effects of colorectal tumour cells and stromal cells: modulation of tumour and stromal cell differentiation and extracellular matrix component production in culture. Int J Exp Pathol 2005;86: 219-229.
39. Pukkila M, Kosunen A, Ropponen K, et al. High stromal versican expression predicts unfavourable outcome in oral squamous cell carcinoma. J Clin Pathol 2007;60:267-272.
40. Makatsori E, Lamari FN, Theocharis AD, et al. Large matrix proteoglycans, versican and perlecan, are expressed and secreted by human leukemic mono-cytes. Anticancer Res 2003;23:3303-3309.
41. Kim S, Takahashi H, Lin WW, et al. Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis. Nature 2009;457:102-106.
42. Hirose J, Kawashima H, Yoshie O, et al. Versican interacts with chemokines and modulates cellular responses. J Biol Chem 2001;276:5228-5234.
43. Negus RP, Stamp GW, Hadley J, et al. Quantitative assessment of the leukocyte infiltrate in ovarian cancer and its relationship to the expression of C-C chemo-kines. Am J Pathol 1997;150:1723-1734.
44. Vicari AP, Ait-Yahia S, Chemin K, et al. Antitumor effects of the mouse chemokine 6Ckine/SLC through angiostatic and immunological mechanisms. J Immunol 2000;165:1992-2000.
45. Kodama J, Hasengaowa, Kusumoto T, et al. Prognostic significance of stromal versican expression in human endometrial cancer. Ann Oncol 2007;18:269-274. (Pubitemid 46323092)
46. Hanekamp EE, Gielen SC, Smid-Koopman E, et al. Consequences of loss of progesterone receptor expression in development of invasive endometrial cancer. Clin Cancer Res 2003;9:4190-4199.
47. Ricciardelli C, Russell DL, Ween MP, et al. Formation of hyaluronan- and versican-rich pericellular matrix by prostate cancer cells promotes cell motility. J Biol Chem 2007;282:10814-10825.
48. Sakko AJ, Ricciardelli C, Mayne K, et al. Modulation of prostate cancer cell attachment to matrix by versican. Cancer Res 2003;63:4786-4791.